表紙
市場調查報告書
商品編碼
1043813

骨關節炎治療藥物市場:按解剖結構、藥物類型、分銷渠道:全球機會分析和行業預測(2021-2030)

Osteoarthritis Therapeutics Market by Anatomy, Drug Type, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030

出版日期: | 出版商: Allied Market Research | 英文 288 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020 年全球骨關節炎治療市場達到 67.541 億美元。

從 2021 年到 2030 年,市場預計將以 8.8% 的複合年增長率增長,到 2030 年達到 156.938 億美元。

全球骨關節炎藥物市場的增長正在增加骨關節炎的患病率,加強政府開發有效治療的力度,以及在藥物開發中使用生物標誌物。主要因素是激增、基於細胞的疼痛管理研究的進展、以及老年人數量的增加。

本報告探討了全球骨關節炎藥物市場,以及市場概況,以及進入市場的公司的解剖結構、藥物類型、分銷渠道、區域趨勢和概況。

目錄

第1章介紹

第2章執行摘要

第3章市場情況

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
    • 主要成功策略
  • 波特五力分析
  • 2020 年主要進入者的定位
  • 市場動態
    • 促進因素
      • 骨關節炎患病率增加
      • 老年人口增加
      • 加強藥物研發活動
    • 抑製器
      • 與使用非甾體抗炎藥相關的風險
      • 用於治療骨關節炎的藥物成本高昂
    • 市場機會
      • 政府政策變化和全球醫療保健成本上升
    • 影響分析
  • COVID-19 對骨關節炎藥物市場的影響分析

第 4 章骨關節炎治療藥物市場:按解剖結構

  • 概覽
    • 市場規模和預測
  • 膝關節骨關節炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 髖關節骨關節炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 腕關節骨關節炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 小關節骨關節炎
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區

第 5 章骨關節炎治療藥物市場:按藥物類型

  • 概覽
    • 市場規模和預測
  • 關節內替代治療
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 非甾體抗炎藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 鎮痛藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 皮質類固醇
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區

第6章骨關節炎治療藥物市場:按分銷渠道

  • 概覽
    • 市場規模和預測
  • 院內藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
      • 院內藥房:按解剖學
    • 市場分析:按國家/地區
  • 零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
      • 零售藥店:按解剖學
    • 市場分析:按國家/地區
  • 網上藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
      • 在線藥房:按解剖學
    • 市場分析:按國家/地區

第 7 章骨關節炎治療藥物市場:按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要市場趨勢、增長因素和機遇
    • 北美骨關節炎藥物市場:按解剖學分類
    • 北美骨關節炎藥物市場:按藥物類型
    • 北美骨關節炎藥物市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要市場趨勢、增長因素和機遇
    • 歐洲骨關節炎治療市場:按解剖學分類
    • 歐洲骨關節炎治療市場:按藥物類型
    • 骨關節炎治療的歐洲市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他
  • 亞太地區
    • 主要市場趨勢、增長因素和機遇
    • 亞太地區骨關節炎治療市場:按解剖學分類
    • 亞太地區骨關節炎治療市場:按藥物類型
    • 亞太地區骨關節炎治療市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他
  • 拉丁美洲、中東、非洲
    • 主要市場趨勢、增長因素和機遇
    • 拉丁美洲、中東、非洲骨關節炎治療市場:按解剖結構
    • 拉丁美洲、中東、非洲骨關節炎治療市場:按藥物類型
    • 拉丁美洲、中東、非洲骨關節炎治療市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他

第 8 章公司簡介

  • Abbott Laboratories
  • Bayer AG
  • Flexion Therapeutics, Inc.
  • GlaxoSmithKline plc.
  • Horizon Therapeutics plc.
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc.
  • Sanofi
  • Zimmer Biomet Holding
目錄
Product Code: A12691

The global osteoarthritis therapeutics market was valued at $6,754.1 million in 2020, and is estimated to reach $15,693.8 million by 2030, growing at a CAGR of 8.8% from 2021 to 2030.

Osteoarthritis is defined as the progressive and chronic condition, which mostly affects the spine, hands, knee, ankles, and hips. It is the most common form of arthritis. It is characterized by the wearing of cartilage, which further results in reduction in friction and causes swelling, loss of motion, and pain. Different types of drugs available for the treatment of osteoarthritis are acetaminophen, duloxetine, and nonsteroidal anti-inflammatory drugs.

The growth of the global osteoarthritis therapeutics market is majorly driven by alarming increase in the prevalence of osteoarthritis; rise in government initiative for development of effective treatment option; surge in application of biomarker in drug development; advancement in cell based research for pain management; and rise in geriatric population. For instance, according to the Lancet, in 2020, approximately 654.1 million people above the age of 40 years were reported to be diagnosed with knee osteoarthritis across the globe. Moreover, the Centers for Disease Control and Prevention, in 2018, announced the CDC arthritis program funds to 13 state programs by DP18-1803, state public health approaches to improve arthritis management and enhance the quality of life. The CDC arthritis program offered an average funding of $289,000 annually from July 1 2018. Furthermore, in September 2021, the American Academy of Orthopedic Surgeons (AAOS) released updates, clinical practice guideline indicating the high molecular weight cross linked hyaluronic treatments for knee osteoarthritis.

Thus, an increase in research activities in osteoarthritis and rise in funds by government and private organization for development of therapeutic drug is expected to propel the growth of the market.

Increase in the number of female population and adoption of different strategy of market players in drug development are the major factors that drive the global osteoarthritis therapeutics market. According to Australian Institute of Health and Welfare, in 2020, it was reported that 3 in 5 individuals diagnosed with osteoarthritis are female. Female is more prone to knee and hip osteoarthritis due to hormonal change. Moreover, increase in incidence of knee osteoarthritis significantly contributes to the market growth. Rise in demand for effective treatment acts a key driving force for the expansion of the global market. Furthermore, governments have taken multiple initiatives to develop a research center, and increase in number of clinical trials for osteoarthritis drug development is expected to boost the market growth.

For instance, in 2020, a researcher from the University of Liverpool, in the UK, developed a new drug candidate APPA (apocynin and paeonol) for the treatment of osteoarthritis, without any harm to the immune system of the body. Thus, advancements in research activities for advanced drug therapeutics in emerging nations are anticipated to provide lucrative opportunities for the market expansion.

However, high cost of drugs used for osteoarthritis and risks associated with the use of nonsteroidal anti-inflammatory drugs, such as stomach ulcer, dizziness, and allergic reaction, are anticipated to hinder the market growth. Rise in the healthcare sector for pain management in osteoarthritis, rise in per capital income, and increase in awareness among the population of early treatment augment the growth of osteoarthritis therapeutics. This has further encouraged many key players to enter emerging markets, thus offering lucrative growth opportunity for the osteoarthritis therapeutics market.

The global osteoarthritis therapeutics market is segmented into anatomy, drug type, distribution channel, and region. By anatomy, the market is categorized into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis, and small joint osteoarthritis.

Depending on drug type, it is fragmented into viscosupplementation agents, nonsteroidal anti-inflammatory drugs, analgesics, and corticosteroids. On the basic of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global osteoarthritis therapeutics market are Abbott Laboratories, Bayer AG, Flexion Therapeutics, Inc., GlaxoSmithKline plc., Horizon Therapeutics plc., Johnson & Johnson, Novartis, Pfizer Inc., Sanofi, and Zimmer Biomet Holding.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global osteoarthritis therapeutics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global osteoarthritis therapeutics market.

KEY MARKET SEGMENTS

By Anatomy

  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis

By Drug Type

  • Viscosupplementation Agents
  • Non-steroidal Anti-inflammatory Drugs
  • Analgesics
  • Corticosteroids

By Distribution Channel

  • Hospital Pharmacies
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis
  • Retail Pharmacies
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis
  • Online Pharmacies
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small Joint Osteoarthritis

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Abbott Laboratories
  • Bayer AG
  • Flexion Therapeutics, Inc.
  • GlaxoSmithKline plc.
  • Horizon Therapeutics plc.
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc.
  • Sanofi
  • Zimmer Biomet Holding

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in prevalence of osteoarthritis
      • 3.5.1.2.Increase in geriatric population
      • 3.5.1.3.Increase in R&D activities for drug development
    • 3.5.2.Restraint
      • 3.5.2.1.Risk associated with the use of non-steroidal anti-inflammatory drugs
      • 3.5.2.1.High cost of drug used for osteoarthritis treatment
    • 3.5.3.Opportunity
      • 3.5.3.1.Change in government policy and increase in healthcare expenditure worldwide
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the osteoarthritis therapeutics market

CHAPTER 4:OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Knee Osteoarthritis
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Hip Osteoarthritis
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Hand Osteoarthritis
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Small Joint Osteoarthritis
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country

CHAPTER 5:OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Viscosupplementation Agents
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Non-steroidal Anti-inflammatory Drugs
    • 5.3.1.Key market trends, growth factors, and opportunitie
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Analgesics
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country
  • 5.5.Corticosteroids
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by region
    • 5.5.3.Market analysis, by country

CHAPTER 6:OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacies
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
      • 6.2.2.1.Hospital pharmacies by anatomy
    • 6.2.3.Market analysis, by country
  • 6.3.Retail Pharmacies
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
      • 6.3.2.1.Retail pharmacies by anatomy
    • 6.3.3.Market analysis, by country
  • 6.4.Online Pharmacies
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
      • 6.4.2.1.Online pharmacies by anatomy
    • 6.4.3.Market analysis, by country

CHAPTER 7:OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America osteoarthritis therapeutics market, by anatomy
    • 7.2.3.North America osteoarthritis therapeutics market, by drug type
    • 7.2.4.North America osteoarthritis therapeutics market, by distribution channel
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. osteoarthritis therapeutics market, by anatomy
      • 7.2.5.1.2.U.S. osteoarthritis therapeutics market, by drug type
      • 7.2.5.1.3.U.S. osteoarthritis therapeutics market, by distribution channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada osteoarthritis therapeutics market, by anatomy
      • 7.2.5.2.2.Canada osteoarthritis therapeutics market, by drug type
      • 7.2.5.2.3.Canada osteoarthritis therapeutics market, by distribution channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico osteoarthritis therapeutics market, by anatomy
      • 7.2.5.3.2.Mexico osteoarthritis therapeutics market, by drug type
      • 7.2.5.3.3.Mexico osteoarthritis therapeutics market, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe osteoarthritis therapeutics market, by anatomy
    • 7.3.3.Europe osteoarthritis therapeutics market, by drug type
    • 7.3.4.Europe osteoarthritis therapeutics market, by distribution channel
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany osteoarthritis therapeutics market, by anatomy
      • 7.3.5.1.2.Germany osteoarthritis therapeutics market, by drug type
      • 7.3.5.1.3.Germany osteoarthritis therapeutics market, by distribution channel
      • 7.3.5.2.France
      • 7.3.5.2.1.France osteoarthritis therapeutics market, by anatomy
      • 7.3.5.2.2.France osteoarthritis therapeutics market, by drug type
      • 7.3.5.2.3.France osteoarthritis therapeutics market, by distribution channel
      • 7.3.5.3.UK
      • 7.3.5.3.1.UK osteoarthritis therapeutics market, by anatomy
      • 7.3.5.3.2.UK osteoarthritis therapeutics market, by drug type
      • 7.3.5.3.3.UK osteoarthritis therapeutics market, by distribution channel
      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy osteoarthritis therapeutics market, by anatomy
      • 7.3.5.4.2.Italy osteoarthritis therapeutics market, by drug type
      • 7.3.5.4.3.Italy osteoarthritis therapeutics market, by distribution channel
      • 7.3.5.5.Spain
      • 7.3.5.5.1.Spain osteoarthritis therapeutics market, by anatomy
      • 7.3.5.5.2.Spain osteoarthritis therapeutics market, by drug type
      • 7.3.5.5.3.Spain osteoarthritis therapeutics market, by distribution channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe osteoarthritis therapeutics market, by anatomy
      • 7.3.5.6.2.Rest of Europe osteoarthritis therapeutics market, by drug type
      • 7.3.5.6.3.Rest of Europe osteoarthritis therapeutics market, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific osteoarthritis therapeutics market, by anatomy
    • 7.4.3.Asia-Pacific osteoarthritis therapeutics market, by drug type
    • 7.4.4.Asia-Pacific osteoarthritis therapeutics market, by distribution channel
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan
      • 7.4.5.1.1.Japan osteoarthritis therapeutics market, by anatomy
      • 7.4.5.1.2.Japan osteoarthritis therapeutics market, by drug type
      • 7.4.5.1.3.Japan osteoarthritis therapeutics market, by distribution channel
      • 7.4.5.2.China
      • 7.4.5.2.1.China osteoarthritis therapeutics market, by anatomy
      • 7.4.5.2.2.China osteoarthritis therapeutics market, by drug type
      • 7.4.5.2.3.China osteoarthritis therapeutics market, by distribution channel
      • 7.4.5.3.Australia
      • 7.4.5.3.1.Australia osteoarthritis therapeutics market, by anatomy
      • 7.4.5.3.2.Australia osteoarthritis therapeutics market, by drug type
      • 7.4.5.3.3.Australia osteoarthritis therapeutics market, by distribution channel
      • 7.4.5.4.India
      • 7.4.5.4.1.India osteoarthritis therapeutics market, by anatomy
      • 7.4.5.4.2.India osteoarthritis therapeutics market, by drug type
      • 7.4.5.4.3.India osteoarthritis therapeutics market, by distribution channel
      • 7.4.5.5.South Korea
      • 7.4.5.5.1.South Korea osteoarthritis therapeutics market, by anatomy
      • 7.4.5.5.2.South Korea osteoarthritis therapeutics market, by drug type
      • 7.4.5.5.3.South Korea osteoarthritis therapeutics market, by distribution channel
      • 7.4.5.6.Rest of Asia-Pacific
      • 7.4.5.6.1.Rest of Asia-Pacific osteoarthritis therapeutics market, by anatomy
      • 7.4.5.6.2.Rest of Asia-Pacific osteoarthritis therapeutics market, by drug type
      • 7.4.5.6.3.Rest of Asia-Pacific osteoarthritis therapeutics market, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA osteoarthritis therapeutics market, by anatomy
    • 7.5.3.LAMEA osteoarthritis therapeutics market, by drug type
    • 7.5.4.LAMEA osteoarthritis therapeutics market, by distribution channel
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil osteoarthritis therapeutics market, by anatomy
      • 7.5.5.1.2.Brazil osteoarthritis therapeutics market, by drug type
      • 7.5.5.1.3.Brazil osteoarthritis therapeutics market, by distribution channel
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia osteoarthritis therapeutics market, by anatomy
      • 7.5.5.2.2.Saudi Arabia osteoarthritis therapeutics market, by drug type
      • 7.5.5.2.3.Saudi Arabia osteoarthritis therapeutics market, by distribution channel
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa osteoarthritis therapeutics market, by anatomy
      • 7.5.5.3.2.South Africa osteoarthritis therapeutics market, by drug type
      • 7.5.5.3.3.South Africa osteoarthritis therapeutics market, by distribution channel
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA osteoarthritis therapeutics market, by anatomy
      • 7.5.5.4.2.Rest of LAMEA osteoarthritis therapeutics market, by drug type
      • 7.5.5.4.3.Rest of LAMEA osteoarthritis therapeutics market, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.Bayer AG
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.Flexion Therapeutics, Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.GlaxoSmithKline plc.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance.
    • 8.4.6.Key strategic moves and developments
  • 8.5.Horizon Therapeutics plc.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.Johnson & Johnson
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.Novartis
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.Pfizer Inc.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Sanofi
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.Zimmer Biomet Holding
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 02.OSTEOARTHRITIS THERAPEUTICS MARKET FOR KNEE OSTEOARTHRITIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.OSTEOARTHRITIS THERAPEUTICS MARKET FOR HIP OSTEOARTHRITIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.OSTEOARTHRITIS THERAPEUTICS MARKET FOR HAND OSTEOARTHRITIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.OSTEOARTHRITIS THERAPEUTICS MARKET FOR SMALL JOINT OSTEOARTHRITIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 07.OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.OSTEOARTHRITIS THERAPEUTICS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 12.OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.HOSPITAL PHARMACIES MARKET, BY ANATOMY, 2020-2030($MILLION)
  • TABLE 14.OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.RETAIL PHARMACIES MARKET, BY ANATOMY, 2020-2030($MILLION)
  • TABLE 16.OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.ONLINE PHARMACIES MARKET, BY ANATOMY, 2020-2030($MILLION)
  • TABLE 18.OSTEOARTHRITIS THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 21.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 22.NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 23.U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 24.U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 25.U.S. OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 26.CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 27.CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 28.CANADA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 29.MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 30.MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 31.MEXICO OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 32.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 33.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 34.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 35.EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 36.GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 37.GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 38.GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 39.FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 40.FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 41.FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 42.UK OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 43.UK OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 44.UK OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 45.ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 46.ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 47.ITALY OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 48.SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 49.SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 50.SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 51.REST OF EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 52.REST OF EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 53.REST OF EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 54.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 55.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 56.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 57.ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 58.JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 59.JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 60.JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 61.CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 62.CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 63.CHINA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 64.AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 65.AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 66.AUSTRALIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 67.INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 68.INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 69.INDIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 71.SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 72.SOUTH KOREA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 76.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 77.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 78.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 79.LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 80.BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 81.BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 82.BRAZIL OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 83.SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 84.SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 85.SAUDI ARABIA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 86.SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 87.SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 88.SOUTH AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 89.REST OF LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY ANATOMY, 2020-2030 ($MILLION)
  • TABLE 90.REST OF LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 91.REST OF LAMEA OSTEOARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 92.ABBOTT: COMPANY SNAPSHOT
  • TABLE 93.ABBOTT: OPERATING SEGMENT
  • TABLE 94.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 95.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96.BAYER: COMPANY SNAPSHOT
  • TABLE 97.BAYER: OPERATING SEGMENT
  • TABLE 98.BAYER: PRODUCT PORTFOLIO
  • TABLE 99.FLEXION THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 100.FLEXION THERAPEUTICS: OPERATING SEGMENT
  • TABLE 101.FLEXION THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 102.GSK: COMPANY SNAPSHOT
  • TABLE 103.GSK: OPERATING SEGMENT
  • TABLE 104.GSK: PRODUCT PORTFOLIO
  • TABLE 105.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106.HORIZON: COMPANY SNAPSHOT
  • TABLE 107.HORIZON: OPERATING SEGMENT
  • TABLE 108.HORIZON: PRODUCT PORTFOLIO
  • TABLE 109.J&J: COMPANY SNAPSHOT
  • TABLE 110.J&J: OPERATING SEGMENT
  • TABLE 111.J&J: PRODUCT PORTFOLIO
  • TABLE 112.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 113.NOVARTIS: OPERATING SEGMENT
  • TABLE 114.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 115.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116.PFIZER: COMPANY SNAPSHOT
  • TABLE 117.PFIZER: OPERATING SEGMENT
  • TABLE 118.PFIZER: PRODUCT PORTFOLIO
  • TABLE 119.SANOFI: COMPANY SNAPSHOT
  • TABLE 120.SANOFI: OPERATING SEGMENT
  • TABLE 121.SANOFI: PRODUCT PORTFOLIO
  • TABLE 122.ZIMMER BIOMET: COMPANY SNAPSHOT
  • TABLE 123.ZIMMER BIOMET: OPERATING SEGMENT
  • TABLE 124.ZIMMER BIOMET: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2020-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2020-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR KNEE OSTEOARTHRITIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR HIP OSTEOARTHRITIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR HAND OSTEOARTHRITIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR SMALL JOINT OSTEOARTHRITIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR VISCOSUPPLEMENTATION AGENTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR ANALGESICS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF OSTEOARTHRITIS THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 24.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 27.BAYER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.BAYER: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 29.BAYER: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 30.FLEXION THERAPEUTICS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 31.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 33.GSK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 34.HORIZON: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.HORIZON: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 36.HORIZON: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 37.J&J: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 38.J&J: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 39.J&J: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 40.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 42.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 43.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 44.PFIZER: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 45.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 46.SANOFI: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 47.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 48.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 49.ZIMMER BIOMET: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.ZIMMER BIOMET: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 51.ZIMMER BIOMET: REVENUE SHARE, BY REGION, 2020 (%)